Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / S•••• G•••••

T••••••• S••••• Capital Partners Completes Growth Investment in S•••• G•••••

Growth investmentclosedannounced Feb 6, 2023closed Feb 6, 2023Fact
What happened
Platform
not an add-on on record
Control
unknown
Share acquired
unknown
Industry
unknown
Target location
MO, US
Seller kind
Founder
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
  • “Our team has worked hard to identify an asset that serves the rapidly growing cell and gene therapy market, and was extremely pleased to find one led by a CEO as passionate as C•••• in the St. Louis area” said M••• S•••••••, Managing Director at TSCP.
  • T••••••• S••••• Capital Partners (TSCP), a private equity firm based in St. Louis, announced today a growth investment in S•••• G••••• (“S••••”), a Chesterfield, MO based provider of regulatory review and biosafety consulting services to pharmaceutical sponsors, CROs, academic health systems, and cl
Side not stated
  • Conducting clinical research in the areas of oncology, rare disease and infectious disease as our primary indications, requires talented colleagues, a shared vision, and a deep knowledge of the life sciences industry” said C•••• J••••••, CEO of S••••.
  • T••••••• S••••• Capital Partners Completes Growth Investment in S•••• G•••••
Evidence
T••••••• S••••• Capital Partners Completes Growth Investment in S•••• G•••••